The power to stop cancer.
The experience to know how.
The dedication to make a difference.

Our purpose

We are bringing the power of precision radiopharmaceuticals into a new era.

Radiopharmaceuticals – a class of precision oncology medicines – are poised to transform the treatment of solid tumors. By hitching a radioisotope to a small molecule, these potent therapies can selectively deliver the proven power of radiation directly to tumors throughout the body.

We are applying our deep drug discovery and development expertise against novel cancer targets from a broad class of surface receptors to produce targeted small molecule radiopharmaceuticals. We seek to create effective new treatments for cancer patients that enable us to go far beyond what’s been done before – bringing us closer to the day we can say “cure.”

Innovative approach, immense possibilities

First-in-class targets for cancer

Targeting GPCRs, a vast and largely unexplored class for radiopharmaceuticals

Differentiated small molecule approach

Broadly enabling foundational platform based on decades of drug development experience

Modular flexible platform

Agnostic to alpha- or beta-emitting radioisotopes

Extensive pipeline

Moving multiple programs rapidly towards clinical development

Dual purpose enabling a targeted medicine approach

The versatile utility of radiopharmaceuticals is core to our development strategy.

Part of a treatment strategy known as theragnostics, radiopharmaceuticals can be used for both therapy and diagnosis.

Radiopharmaceuticals, when tethering a radionuclide suitable for imaging, create a map of cancerous tumors in the body that provides precise diagnostic information. From the imaging results, the patients who are most likely to respond are identified and treated with individualized regiments of the therapeutic version of the same radiopharmaceutical. This precision medicine approach seeks to make substantial improvements in clinical outcomes.

Approach

Broadly enabling technology to dramatically expand the application of radiopharmaceuticals.
We deliver targeted effects of radiation via optimal drug design.
small-molecule radiopharmaceutical targeting GPCR
We have built the only platform for the rapid discovery and development of novel small molecule radiopharmaceuticals that bind to GPCRs overexpressed on cancer cells.

Small molecules, tethered with powerful radioisotopes, are designed to exquisitely bind to receptors overexpressed in cancer and deliver powerful radiation to kill tumors, without affecting normal tissue.

Our unique approach marries a vast knowledge of GPCR biology with unrivaled proficiency in small molecule medicinal chemistry to develop potent and highly selective radiopharmaceuticals. We take a fit-for-purpose approach, pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.

Novel targets for solid tumors

GPCR family tree showing 132 peptide and protein GPCRs
GPCRs – expansive and largely unexplored target space for radiopharmaceuticals

Largest gene family in humans

132 known protein/receptor pairs

>65 with increased tumor expression

Given GPCR overexpression in many tumors, they can be targeted in a vast range of cancer indications, from common to rare tumors.

Collaborators
and investors

The Radionetics platform was built and incubated within Crinetics (CRNX), a leader in GPCR-targeted drug development, prior to our spin out and financing by 5AM Ventures and Frazier Healthcare in October 2021. Our continued collaboration with Crinetics accelerates our early discovery efforts.

Crinetics Pharmaceuticals
5AM Ventures
Frazier Healthcare Partners

Board
of
directors

Scott Struthers, Ph.D.
Chairman; CEO
Crinetics
Dan Estes, Ph.D.
General Partner
Frazier Healthcare Partners
David Allison, Ph.D.
Partner
5AM Ventures
Zachary Hornby
CEO
Boundless Bio
Nishan de Silva, M.D.
CEO
Radionetics Oncology

Careers

join us

Join a fast-growing company with a deep foundation and vast opportunity, where every contribution matters.

Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.

positions
Nishan de Silva headshot

Nishan de Silva, M.D.

Chief Executive Officer

Nishan de Silva, M.D. serves as Chief Executive Officer, bringing over 20 years of experience in biotechnology operations, biopharmaceutical venture capital, and healthcare management consulting. He was previously Chief Executive Officer and Director of AFYX Therapeutics, a private biotechnology company focused on mucosal diseases. Prior to that, he served as president, chief operating officer, and director of Poseida Therapeutics (PSTX), a cell and gene therapy-focused biopharmaceutical company, where he oversaw clinical development, regulatory, manufacturing, finance, and business development activities. Prior to Poseida, he was chief financial officer and vice president of finance and strategy at Ligand Pharmaceuticals Inc. (LGND). Dr. de Silva holds a M.D. from The University of Pennsylvania School of Medicine, M.B.A. with Distinction in healthcare management from The Wharton School and B.A. summa cum laude in biology from Harvard University.

scroll to top